|Articles|June 12, 2020
Survival benefit in advanced or metastatic breast cancer with visceral metastases
Author(s)Lindsey Carr, Editor
Findings from a new study show significant overall survival benefit of Novartis’ ribociclib in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with visceral metastases.
Advertisement
The findings are from a subgroup analysis of the phase 3 MONALESSA-3 and MONALEESA-7 trials and were presented during the ASCO20 Virtual Scientific Program.
Learn more and read the full article from
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA working with manufacturers to increase access to estradiol transdermal patches
2
ACOG's 2026-27 respiratory virus immunization recommendations in pregnancy, postpartum
3
Kevin Ault, MD, on the maternal and fetal benefits of COVID-19 and flu vaccination in pregnancy
4
Kevin Ault, MD, on the extended RSV window in ACOG's 2026-27 immunization guidance
5